ZA200605379B - A medical product comprising tiotropium in a moistureproof container - Google Patents
A medical product comprising tiotropium in a moistureproof container Download PDFInfo
- Publication number
- ZA200605379B ZA200605379B ZA200605379A ZA200605379A ZA200605379B ZA 200605379 B ZA200605379 B ZA 200605379B ZA 200605379 A ZA200605379 A ZA 200605379A ZA 200605379 A ZA200605379 A ZA 200605379A ZA 200605379 B ZA200605379 B ZA 200605379B
- Authority
- ZA
- South Africa
- Prior art keywords
- container
- dry
- high barrier
- dose
- tiotropium
- Prior art date
Links
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims abstract description 51
- 229940110309 tiotropium Drugs 0.000 title claims abstract description 50
- 229940127554 medical product Drugs 0.000 title claims abstract description 17
- 230000004888 barrier function Effects 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000010419 fine particle Substances 0.000 claims abstract description 19
- 229910052782 aluminium Inorganic materials 0.000 claims description 23
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 23
- 229940112141 dry powder inhaler Drugs 0.000 claims description 16
- 239000011888 foil Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 239000002861 polymer material Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 3
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims description 3
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 230000003454 betamimetic effect Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 150000005480 nicotinamides Chemical class 0.000 claims description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000002876 beta blocker Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 22
- 208000023504 respiratory system disease Diseases 0.000 abstract description 5
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 35
- 239000002775 capsule Substances 0.000 description 35
- 229940046810 spiriva Drugs 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 239000003814 drug Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 12
- 239000007903 gelatin capsule Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 8
- 229940126534 drug product Drugs 0.000 description 8
- 229960000257 tiotropium bromide Drugs 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000013112 stability test Methods 0.000 description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 5
- 239000000812 cholinergic antagonist Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- -1 Spiriva® Chemical compound 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010006440 Bronchial obstruction Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100027377 HBS1-like protein Human genes 0.000 description 1
- 101001009070 Homo sapiens HBS1-like protein Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012710 chemistry, manufacturing and control Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012632 extractable Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000004920 heat-sealing lacquer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Table Devices Or Equipment (AREA)
- Containers Having Bodies Formed In One Piece (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0303269A SE0303269L (sv) | 2003-12-03 | 2003-12-03 | Medicinsk produkt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200605379B true ZA200605379B (en) | 2008-07-30 |
Family
ID=29778162
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604618A ZA200604618B (en) | 2003-12-03 | 2004-12-02 | Medical product containing tiotropium |
| ZA200605379A ZA200605379B (en) | 2003-12-03 | 2004-12-02 | A medical product comprising tiotropium in a moistureproof container |
| ZA200604616A ZA200604616B (en) | 2003-12-03 | 2004-12-02 | Inhalable tiotropium and container therefor |
| ZA200605380A ZA200605380B (en) | 2003-12-03 | 2004-12-02 | Pre-metered dry powder inhaler for moisture-senitive medicaments |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604618A ZA200604618B (en) | 2003-12-03 | 2004-12-02 | Medical product containing tiotropium |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604616A ZA200604616B (en) | 2003-12-03 | 2004-12-02 | Inhalable tiotropium and container therefor |
| ZA200605380A ZA200605380B (en) | 2003-12-03 | 2004-12-02 | Pre-metered dry powder inhaler for moisture-senitive medicaments |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20050124644A1 (fr) |
| EP (1) | EP1706099B1 (fr) |
| JP (1) | JP2007513152A (fr) |
| KR (1) | KR101124071B1 (fr) |
| CN (2) | CN1913873B (fr) |
| AT (1) | ATE507821T1 (fr) |
| AU (1) | AU2004294886B2 (fr) |
| BR (1) | BRPI0417155A (fr) |
| CA (1) | CA2547781A1 (fr) |
| CY (1) | CY1111735T1 (fr) |
| DE (1) | DE602004032575D1 (fr) |
| DK (1) | DK1706099T3 (fr) |
| ES (1) | ES2362750T3 (fr) |
| HK (1) | HK1100643A1 (fr) |
| IL (1) | IL175887A (fr) |
| MX (1) | MXPA06006238A (fr) |
| NZ (1) | NZ547905A (fr) |
| PL (1) | PL1706099T3 (fr) |
| PT (1) | PT1706099E (fr) |
| RU (1) | RU2369385C2 (fr) |
| SE (1) | SE0303269L (fr) |
| SG (1) | SG148206A1 (fr) |
| SI (1) | SI1706099T1 (fr) |
| WO (1) | WO2005053644A1 (fr) |
| ZA (4) | ZA200604618B (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US7080644B2 (en) | 2000-06-28 | 2006-07-25 | Microdose Technologies, Inc. | Packaging and delivery of pharmaceuticals and drugs |
| DE60318938T2 (de) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | Inhalationsgerät |
| KR101315690B1 (ko) * | 2003-12-03 | 2013-10-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 습기 민감성 의약용 기-계량된 건조 분말 흡입기 |
| EP1691782A1 (fr) * | 2003-12-03 | 2006-08-23 | Microdrug AG | Produit medical contenant du tiotropium |
| SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
| CN1925887B (zh) | 2004-02-24 | 2010-12-22 | 微计量治疗公司 | 方向流传感器吸入器 |
| WO2006023849A2 (fr) | 2004-08-20 | 2006-03-02 | Mannkind Corporation | Catalyse de la synthese de dicetopiperazine |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
| IN2014DN09128A (fr) | 2005-09-14 | 2015-07-10 | Mannkind Corp | |
| BRPI0707991B8 (pt) | 2006-02-22 | 2021-05-25 | Mannkind Corp | métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US8439033B2 (en) | 2007-10-09 | 2013-05-14 | Microdose Therapeutx, Inc. | Inhalation device |
| US8371294B2 (en) | 2008-02-29 | 2013-02-12 | Microdose Therapeutx, Inc. | Method and apparatus for driving a transducer of an inhalation device |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| EP3281663B8 (fr) * | 2008-06-13 | 2022-09-21 | MannKind Corporation | Inhalateur de poudre sèche alimenté par la respiration pour l'administration de médicaments |
| BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| WO2010097115A1 (fr) | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol |
| WO2010105094A1 (fr) | 2009-03-11 | 2010-09-16 | Mannkind Corporation | Appareil, système et procédé de mesure de résistance d'un inhalateur |
| US8985101B2 (en) | 2009-05-21 | 2015-03-24 | Microdose Therapeutx, Inc. | Method and device for clamping a blister within a dry powder inhaler |
| BRPI1011194A2 (pt) | 2009-05-21 | 2016-12-27 | Microdose Therapeutx Inc | sistema de receptáculo rotativo para inalador de pó seco |
| WO2010144789A2 (fr) | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Microparticules de dicétopipérazine avec des surfaces spécifiques définies |
| WO2011056889A1 (fr) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | Appareil et méthode de simulation d'efforts d'inhalation |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| CA2784041C (fr) | 2010-01-05 | 2017-11-07 | Microdose Therapeutx, Inc. | Dispositif et procede d'inhalation |
| AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
| EP2694402B1 (fr) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Emballage coque pour cartouches pharmaceutiques |
| WO2012174472A1 (fr) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | Microparticules de dicétopipérazine de capacité élevée |
| CA2852536A1 (fr) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Procedes et compositions pour traiter la douleur |
| WO2014012069A2 (fr) | 2012-07-12 | 2014-01-16 | Mannkind Corporation | Systèmes et procédés de libération de médicament en poudre sèche |
| EP2911690A1 (fr) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Compositions et procédés de vaccin antigrippal inhalable |
| WO2014074797A1 (fr) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Poudres pulmonaires de densité ultra basse |
| KR102499439B1 (ko) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | 미세결정성 디케토피페라진 조성물 및 방법 |
| CA2918369C (fr) | 2013-07-18 | 2021-06-29 | Mannkind Corporation | Compositions pharmaceutiques en poudre seche stables a la chaleur et procedes |
| CA2920488C (fr) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Appareil d'insufflation et procedes |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| WO2018071435A1 (fr) | 2016-10-11 | 2018-04-19 | Microdose Therapeutx, Inc. | Inhalateur et ses procédés d'utilisation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6536427B2 (en) * | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| US5544647A (en) * | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5692496A (en) * | 1995-08-02 | 1997-12-02 | Innovative Devices, Llc | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament |
| AU6014098A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Aerosolized hydrophobic drug |
| US6645466B1 (en) * | 1998-11-13 | 2003-11-11 | Jago Research Ag | Dry powder for inhalation |
| US6270869B1 (en) * | 1998-12-02 | 2001-08-07 | Alusuisse Technology & Management Ltd. | Cold formable laminate films |
| IL146886A0 (en) * | 1999-06-05 | 2002-08-14 | Innovata Biomed Ltd | Medicament delivery system |
| ES2213608T3 (es) * | 1999-10-11 | 2004-09-01 | Innovata Biomed Limited | Dispositivo de administracion de medicamento con revestimiento resistente a la humedad. |
| SE9904706D0 (sv) * | 1999-12-21 | 1999-12-21 | Astra Ab | An inhalation device |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) * | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| SE517227C2 (sv) * | 2000-09-25 | 2002-05-14 | Microdrug Ag | Inhalator för torrt pulver med folieskärare |
| IL149984A0 (en) * | 2000-10-12 | 2002-12-01 | Boehringer Ingelheim Pharma | Novel tiotropium-containing inhalation powder |
| EA009068B1 (ru) * | 2000-10-31 | 2007-10-26 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Ингаляционная композиция в виде раствора с солью тиотропия |
| DE10126924A1 (de) * | 2001-06-01 | 2002-12-05 | Boehringer Ingelheim Pharma | Inhalationskapseln |
| US20030078947A1 (en) * | 2001-10-12 | 2003-04-24 | Intel Corporation | Methods for assigning unique identifiers in a distributed fault tolerant application |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| US6591832B1 (en) * | 2002-02-21 | 2003-07-15 | Saint-Gobain Calmar Inc. | Dry powder dispenser |
| US20030235538A1 (en) * | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
| UA80123C2 (en) * | 2002-04-09 | 2007-08-27 | Boehringer Ingelheim Pharma | Inhalation kit comprising inhalable powder of tiotropium |
| SE524990C2 (sv) * | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
| SE525027C2 (sv) * | 2002-04-12 | 2004-11-16 | Microdrug Ag | Anordning utgörande en pulverlufthyvel |
| SE524957C2 (sv) * | 2002-04-12 | 2004-11-02 | Microdrug Ag | Förfarande för uppdelning och fördelning i luft av torrt pulvermedikament |
| GB0225621D0 (en) * | 2002-11-02 | 2002-12-11 | Glaxo Group Ltd | Medicament carrier |
| CN1292748C (zh) * | 2003-03-05 | 2007-01-03 | 南昌弘益科技有限公司 | 噻托溴铵吸入粉雾剂及其制备工艺 |
| US20050055014A1 (en) * | 2003-08-04 | 2005-03-10 | Coppeta Jonathan R. | Methods for accelerated release of material from a reservoir device |
| SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
| SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
| SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
| SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
-
2003
- 2003-12-03 SE SE0303269A patent/SE0303269L/sv unknown
- 2003-12-08 US US10/728,986 patent/US20050124644A1/en not_active Abandoned
-
2004
- 2004-12-02 MX MXPA06006238A patent/MXPA06006238A/es active IP Right Grant
- 2004-12-02 ES ES04801707T patent/ES2362750T3/es active Active
- 2004-12-02 CN CN2004800413545A patent/CN1913873B/zh active Active
- 2004-12-02 EP EP04801707A patent/EP1706099B1/fr not_active Revoked
- 2004-12-02 ZA ZA200604618A patent/ZA200604618B/xx unknown
- 2004-12-02 WO PCT/SE2004/001790 patent/WO2005053644A1/fr active Application Filing
- 2004-12-02 PL PL04801707T patent/PL1706099T3/pl unknown
- 2004-12-02 CA CA002547781A patent/CA2547781A1/fr not_active Abandoned
- 2004-12-02 SI SI200431694T patent/SI1706099T1/sl unknown
- 2004-12-02 NZ NZ547905A patent/NZ547905A/en unknown
- 2004-12-02 ZA ZA200605379A patent/ZA200605379B/en unknown
- 2004-12-02 DK DK04801707.3T patent/DK1706099T3/da active
- 2004-12-02 ZA ZA200604616A patent/ZA200604616B/xx unknown
- 2004-12-02 SG SG200808774-4A patent/SG148206A1/en unknown
- 2004-12-02 AU AU2004294886A patent/AU2004294886B2/en active Active
- 2004-12-02 DE DE602004032575T patent/DE602004032575D1/de active Active
- 2004-12-02 RU RU2006122849/15A patent/RU2369385C2/ru active
- 2004-12-02 ZA ZA200605380A patent/ZA200605380B/en unknown
- 2004-12-02 BR BRPI0417155-1A patent/BRPI0417155A/pt not_active Application Discontinuation
- 2004-12-02 KR KR1020067011729A patent/KR101124071B1/ko active IP Right Grant
- 2004-12-02 JP JP2006542535A patent/JP2007513152A/ja active Pending
- 2004-12-02 PT PT04801707T patent/PT1706099E/pt unknown
- 2004-12-02 AT AT04801707T patent/ATE507821T1/de active
- 2004-12-02 CN CN2004800412129A patent/CN1913872B/zh active Active
-
2006
- 2006-05-24 IL IL175887A patent/IL175887A/en active IP Right Grant
- 2006-06-08 US US11/448,773 patent/US20060257327A1/en not_active Abandoned
-
2007
- 2007-08-03 HK HK07108468.9A patent/HK1100643A1/xx unknown
-
2008
- 2008-10-21 US US12/255,086 patent/US20090041682A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/417,814 patent/US20090192185A1/en not_active Abandoned
-
2011
- 2011-07-22 CY CY20111100727T patent/CY1111735T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004294886B2 (en) | A medical product comprising tiotropium in a moisture-proof container | |
| AU2004294888B2 (en) | Inhalable tiotropium and container therefor | |
| US20090038612A1 (en) | Medical product containing tiotropium | |
| US20090025719A1 (en) | Pre-metered dry powder inhaler for moisture-sensitive medicaments | |
| EP1691783B1 (fr) | Poudre seche predosee a inhaler pour medicaments hydrosensibles | |
| US20070020198A1 (en) | Medical product containing tiotropium |